Keyword: Vertex Pharmaceuticals
Vertex and CRISPR will co-develop a beta-thalassemia and sickle cell treatment, the first to come out of their $105 million partnership.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada names its fourth CEO in less than two years, Vertex poaches CFO from Ironwood.
The French drugmaker handed over another slice of the €290 million in milestones tied to the drug after getting a look at phase 1 data.
The efficacy seen in the trials suggests the combinations can treat most cystic fibrosis patients, opening the door to a multibillion-dollar market.
Johnson & Johnson has listed the pipeline prospects it expects to drive the growth in its biopharma business for years to come.
Biotech executives and the head of the NIH are set to meet with top White House officials today.
Corbus Pharmaceuticals has posted positive top-line data from its midstage trial of Resunab in certain cystic fibrosis (CF) patients as it plots future trials and talks with regulators.
Vertex could pay out as much as $250 million to gain full access to Concert Pharmaceuticals’ midstage cystic fibrosis candidate CTP-656, a tweaked version of its own Kalydeco, as it eyes combo uses that target the underlying causes of the fatal disease.
Merck KGaA has paid Vertex Pharmaceuticals $230 million (€219 million) upfront for the rights to four cancer programs.